Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib vs Abemaciclib/Ribociclib in HR+/HER2- Early Breast Cancer
NCT07706933Phase 3Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Nov 2026
- Primary completion
- Jun 2028
01
Overview
A Phase 3 trial of dalpiciclib in breast cancer, sponsored by Henan Cancer Hospital. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07706933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07706933.